Medifast (NYSE:MED) Issues FY 2026 Earnings Guidance

Medifast (NYSE:MED) issued an update on its FY 2026 earnings guidance on Monday. The company provided EPS guidance of -1.750–0.250 for the period, compared to the consensus earnings per share estimate of -1.870. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $281.0 million. Medifast also updated its Q3 2026 guidance to -0.650–0.150 EPS.

Wall Street Analysts Forecast Growth

MED has been the subject of several recent research reports. Zacks Research upgraded shares of Medifast from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Weiss Ratings lowered shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

Medifast Trading Down 1.1%

NYSE MED opened at $9.72 on Tuesday. Medifast has a 12 month low of $9.22 and a 12 month high of $15.11. The stock has a market cap of $108.13 million, a price-to-earnings ratio of -5.31 and a beta of 0.65. The company’s 50 day moving average is $11.05 and its two-hundred day moving average is $11.04.

Medifast (NYSE:MED) last posted its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million during the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Sell-side analysts forecast that Medifast will post -1.97 EPS for the current year.

Insider Activity

In other Medifast news, Director Scott Schlackman bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $12.53 per share, with a total value of $31,325.00. Following the purchase, the director owned 30,549 shares of the company’s stock, valued at $382,778.97. This trade represents a 8.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

More Medifast News

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: Medifast reported a second-quarter loss of $0.28 per share, substantially better than the consensus estimate for a $0.65–$0.67 loss. Revenue of $76.4 million also exceeded estimates of approximately $72.7 million. Medifast Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Management’s full-year 2026 EPS outlook of a $0.25 to $1.75 loss is better than the consensus estimate for a $1.87 loss. The company maintained a sizable liquidity position, ending the quarter with $169.8 million in cash, equivalents and investments and no debt. Medifast Announces Second Quarter 2026 Financial Results
• Positive Sentiment: The company highlighted its “3.0” metabolic-health strategy, stabilized revenue trends and improving productivity among its independent coaches. Chief Executive Officer Daniel Chard also purchased 17,678 shares in the past six months, a potential signal of management confidence. Medifast 3.0 Strategy and Coach Productivity
• Neutral Sentiment: Third-quarter guidance calls for revenue of $60 million to $80 million and an adjusted loss of $0.15 to $0.65 per share. The ranges broadly bracket analyst expectations of $68 million in revenue and a $0.62 loss, suggesting limited near-term visibility. Medifast Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue fell 27.6% year over year to $76.4 million, while the company swung to a $3.1 million net loss from $2.5 million of profit a year earlier. Active earning coaches plunged 48.7% to 11,700, indicating continued customer-acquisition and distribution challenges.

Hedge Funds Weigh In On Medifast

Several institutional investors have recently bought and sold shares of MED. Charles Schwab Investment Management Inc. boosted its holdings in shares of Medifast by 30.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after purchasing an additional 181,618 shares during the last quarter. Bank of America Corp DE increased its stake in Medifast by 14.2% in the 3rd quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock worth $6,186,000 after acquiring an additional 56,174 shares during the last quarter. Lido Advisors LLC purchased a new stake in shares of Medifast during the 3rd quarter worth approximately $4,521,000. Dimensional Fund Advisors LP grew its holdings in shares of Medifast by 9.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 326,240 shares of the specialty retailer’s stock valued at $3,484,000 after purchasing an additional 27,871 shares in the last quarter. Finally, Steamboat Capital Partners LLC purchased a new stake in Medifast during the fourth quarter valued at $2,952,000. 95.51% of the stock is owned by hedge funds and other institutional investors.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.